Healthcare Industry News: V.A.C. Therapy
News Release - April 26, 2010
KCI Statement on FDA Medical Device Home Use InitiativeSAN ANTONIO--(HSMN NewsFeed)--Kinetic Concepts, Inc. (NYSE: KCI ) issued the following statement today from Catherine Burzik, KCI president and CEO, regarding the U.S. Food and Drug Administration’s (FDA) medical device home use initiative:
“KCI applauds the FDA for launching this important initiative to ensure that complex medical devices are used safely in the home by caregivers and patients. We have made it our priority and unwavering responsibility to help caregivers and patients understand how to use our advanced treatments safely. This includes offering a robust education and training program, employing highly trained clinical support staff and providing easy-to-read, patient-specific labeling.
KCI’s V.A.C.® Therapy is the only negative pressure wound therapy product to have a FDA home use indication based on substantial clinical and scientific data. The people of KCI have a deep commitment to patient care and safety and support the FDA’s goals for this initiative.”
Kinetic Concepts, Inc. (NYSE:KCI ) is a leading global medical technology company devoted to the discovery, development, manufacture and marketing of innovative, high-technology therapies and products for the wound healing, tissue regeneration and therapeutic support system markets. Headquartered in San Antonio, Texas, KCI’s legacy spans more than three decades and is rooted in a passion for healing wounds and restoring lives around the world through innovative, clinically proven therapies. The Company employs 6,800 people and markets its products in 20 countries. For more information about KCI, and how its products are changing the practice of medicine, visit www.KCI1.com.
Source: Kinetic Concepts
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.